Surveillance of Suicide Ideation in Adolescents (VISIA)
Launched by SERVICIO GALLEGO DE SALUD · Mar 26, 2024
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Introduction:
The Surveillance of Suicide Ideation in Adolescents (VISIA) project is a collaborative effort involving a diverse research team encompassing experts in mental disorders and seasoned researchers in data science, specializing in intelligent services and applications across various domains. The project aims to address the shortcomings identified in existing research. The initial phase of this endeavor seeks to validate an artificial intelligence (AI) algorithm capable of distinguishing individuals with suicidal ideation from a control group by analyzing multimodal variables. The...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ideation Group
- • Participants must be between 11 and 16 years old.
- • Patients who do not meet any of the exclusion criteria and whose parents (both), guardians, or legal representatives accept their voluntary participation in the study. In case of divorce, authorization from both parents will be required.
- • Patients receive care in child and adolescent psychiatry or psychology services and currently have suicidal ideation.
- • Patients may have a previous follow-up, as long as they have suicidal ideation at the present moment, or they may be new consultations and may be receiving pharmacological treatment (which will be documented in the study).
- • Clinical Population Group
- • Participants must be between 11 and 16 years old.
- • Patients who do not meet any of the exclusion criteria and whose parents (both), guardians, or legal representatives accept their voluntary participation in the study. In case of divorce, authorization from both parents will be required.
- • Patients receive care in child and adolescent psychiatry or psychology services for any reason other than those listed as exclusion criteria.
- • Patients have not had suicidal ideation in the past year. Patients may have a previous follow-up or may be new consultations, and they may be receiving pharmacological treatment (which will be documented in the study).
- • General Population Group
- • Participants must be between 11 and 16 years old.
- • Students who do not meet any of the exclusion criteria and whose parents (both), guardians, or legal representatives accept their voluntary participation in the study. In case of divorce, authorization from both parents will be required.
- • Students must declare that they have not received psychiatric or psychological follow-up before, nor have they had suicidal ideation in the past year.
- Exclusion Criteria (applicable to all groups):
- * Neurodevelopmental disorders or speech disorders affecting verbal communication capacity, specifically including:
- • Autism Spectrum Disorder grades 2 and 3.
- • Communication disorders (selective mutism, language disorder, phonological disorder, childhood-onset fluency disorder, social communication disorder).
- • Individuals with hearing impairment and verbal language impairment.
- • Individuals with moderate and severe intellectual disabilities.
- • Individuals with psychotic disorders.
About Servicio Gallego De Salud
Servicio Gallego de Salud (Sergas) is the public health service of the autonomous community of Galicia, Spain, dedicated to providing comprehensive healthcare services to its population. As a clinical trial sponsor, Sergas plays a pivotal role in advancing medical research and innovation by facilitating the development of new therapies and treatment protocols. It emphasizes a commitment to ethical standards, patient safety, and scientific rigor in all its research initiatives. By collaborating with various stakeholders, including academic institutions and industry partners, Sergas aims to enhance healthcare outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vigo, Pontevedra, Spain
Santiago De Compostela, A Coruña, Spain
Vigo, Pontevedra, Spain
Ourense, , Spain
Santiago De Compostela, , Spain
Patients applied
Trial Officials
Alejandro García Caballero
Principal Investigator
University Hospital Complex of Ourense
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported